TearLab Corp  

(Public, NASDAQ:TEAR)   Watch this stock  
Find more results for Paul Lindstrom
3.81
-0.03 (-0.78%)
Real-time:   2:35PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.75 - 3.92
52 week 3.30 - 13.55
Open 3.82
Vol / Avg. 208,091.00/376,754.00
Mkt cap 126.98M
P/E     -
Div/yield     -
EPS -0.79
Shares 33.59M
Beta 3.13
Inst. own 62%
Aug 14, 2014
Tearlab Corp at Canaccord Genuity Growth Conference
Aug 7, 2014
Q2 2014 Tearlab Corp Earnings Call
Aug 7, 2014
Q2 2014 TearLab Corp Earnings Release
Jun 11, 2014
TearLab Corp Annual Shareholder Meeting
May 28, 2014
TearLab Corp at Craig-Hallum Institutional Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -131.96% -197.95%
Operating margin -140.61% -121.37%
EBITD margin - -108.62%
Return on average assets -46.54% -78.25%
Return on average equity -55.23% -103.15%
Employees 101 -
CDP Score - -

Address

Suite 200, 7360 Carroll Rd
SAN DIEGO, CA 92121
United States - Map
+1-858-4556006 (Phone)
+1-858-8120540 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TearLab Corp. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). TearLab Research, Inc., its wholly owned subsidiary, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (i.e. glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company's business. Its TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. In March 2014, the Company acquired assets of the OcuHub business unit from AOAExcel, Inc.

Officers and directors

Elias Vamvakas Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Joseph Jensen President, Chief Operating Officer
Age: 42
Bio & Compensation  - Reuters
William G. Dumencu Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Tracy Puckett Vice President - Marketing
Age: 50
Bio & Compensation  - Reuters
Michael Berg Vice President - Regulatory
Age: 61
Bio & Compensation  - Reuters
Paul Smith Vice President - International
Bio & Compensation  - Reuters
Anthony E. Altig Independent Director
Age: 58
Bio & Compensation  - Reuters
Thomas N. Davidson Jr. Independent Director
Age: 55
Bio & Compensation  - Reuters
Adrienne L. Graves Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Paul M. Karpecki Independent Director
Age: 47
Bio & Compensation  - Reuters